Investigators evaluated ctDNA as a prognostic marker for patients with follicular lymphoma in the phase III GALLIUM trial.

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is associated ...

Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...

Quest Diagnostics (NYSE:DGX) announced a US$500 million senior notes offering. The company also entered a multi year clinical partnership with City of Hope focused on advanced ctDNA testing. The ...

Droplet digital PCR measurements of ctDNA may accurately identify patients with melanoma who are at high risk of recurrence. Patients who were ctDNA positive had worse recurrence-free and overall ...

ctDNA testing could help doctors track response, reduce unnecessary chemo, and identify relapse early for patients with aggressive B cell lymphomas. Dr. Hua-Jay Cherng, a hematologist oncologist at ...

The nonsteroidal anti-inflammatory (NSAID) class of drugs, often used to treat pain and fever, includes medications like aspirin that have shown potential in CRC treatment. NSAIDs target ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

Results of two phase 3 studies — IMvigor011 and DYNAMIC-III — presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2025 suggest that circulating tumor DNA (ctDNA) could help ...